Moberg Pharma subsidiary OncoZenge announced that the European Patent Office has granted the firm patent No. 3,284,459, which protects its BupiZenge lozenge.
The sustained-release lozenge containing bupivacaine is currently being developed for the treatment of pain due to oral mucositis. The patent is in effect until 2032 and is a divisional of the previously granted European patent No. 2,701,681. The previous patent specifically protects the use of lozenges for the treatment of pain due to oral mucositis for cancer patients.
BupiZenge already has similar patents in the U.S. and Canada, OncoZenge said.
%20nov12024.q9h8imREpF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20nov12024.q9h8imREpF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
